BridgeBio Pharma, Inc. (NASDAQ:BBIO) CEO Sells $2,517,750.00 in Stock

BridgeBio Pharma, Inc. (NASDAQ:BBIO) CEO Neil Kumar sold 75,000 shares of the stock in a transaction on Tuesday, February 25th. The shares were sold at an average price of $33.57, for a total value of $2,517,750.00. Following the transaction, the chief executive officer now directly owns 5,023,447 shares of the company’s stock, valued at approximately $168,637,115.79. This trade represents a 1.47 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink.

Neil Kumar also recently made the following trade(s):

• On Wednesday, February 19th, Neil Kumar sold 31,543 shares of BridgeBio Pharma stock. The shares were sold at an average price of $36.14, for a total value of $1,139,964.02.
• On Tuesday, January 28th, Neil Kumar sold 326,932 shares of BridgeBio Pharma stock. The shares were sold at an average price of $36.29, for a total value of $11,864,362.28.

BridgeBio Pharma Stock Performance

Shares of BBIO stock opened at $34.90 on Friday. BridgeBio Pharma, Inc. has a 52-week low of $21.62 and a 52-week high of $39.47. The company has a market capitalization of $6.64 billion, a PE ratio of -12.25 and a beta of 1.07. The business’s fifty day moving average is $32.68 and its 200 day moving average is $28.32.

BridgeBio Pharma (NASDAQ:BBIO) last issued its quarterly earnings data on Thursday, February 20th. The company reported ($1.31) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.09) by ($0.22). The company had revenue of $5.88 million during the quarter, compared to the consensus estimate of $4.04 million. On average, sell-side analysts forecast that BridgeBio Pharma, Inc. will post -3.67 EPS for the current fiscal year.

Institutional Investors Weigh In On BridgeBio Pharma

Institutional investors and hedge funds have recently made changes to their positions in the business. Steward Partners Investment Advisory LLC raised its position in shares of BridgeBio Pharma by 85.8% in the fourth quarter. Steward Partners Investment Advisory LLC now owns 1,022 shares of the company’s stock worth $28,000 after buying an additional 472 shares in the last quarter. Itau Unibanco Holding S.A. purchased a new stake in BridgeBio Pharma during the fourth quarter valued at about $41,000. Sterling Capital Management LLC raised its position in BridgeBio Pharma by 554.6% during the fourth quarter. Sterling Capital Management LLC now owns 1,787 shares of the company’s stock valued at $49,000 after purchasing an additional 1,514 shares in the last quarter. GF Fund Management CO. LTD. purchased a new stake in BridgeBio Pharma during the fourth quarter valued at about $109,000. Finally, Advisors Asset Management Inc. raised its position in BridgeBio Pharma by 56.1% during the third quarter. Advisors Asset Management Inc. now owns 4,576 shares of the company’s stock valued at $117,000 after purchasing an additional 1,645 shares in the last quarter. Hedge funds and other institutional investors own 99.85% of the company’s stock.

Analyst Ratings Changes

BBIO has been the subject of several research reports. Evercore ISI increased their price objective on BridgeBio Pharma from $45.00 to $50.00 and gave the company an “outperform” rating in a report on Monday, December 23rd. Bank of America increased their price objective on BridgeBio Pharma from $42.00 to $45.00 and gave the company a “buy” rating in a report on Monday, November 25th. HC Wainwright reaffirmed a “buy” rating and issued a $49.00 price target on shares of BridgeBio Pharma in a report on Thursday, February 13th. Scotiabank raised their price target on BridgeBio Pharma from $49.00 to $52.00 and gave the stock a “sector outperform” rating in a report on Friday, February 21st. Finally, Citigroup raised their price target on BridgeBio Pharma from $45.00 to $49.00 and gave the stock a “buy” rating in a report on Friday, February 21st. One analyst has rated the stock with a hold rating and twelve have issued a buy rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $51.67.

BridgeBio Pharma Company Profile

BridgeBio Pharma, Inc, a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD.